期刊文献+

组蛋白去乙酰化酶抑制剂SAHA联合溶瘤腺病毒ZD55-IL-24诱导SW480细胞凋亡 被引量:4

Apoptosis in SW480 Cells Induced by Combining Oncolytic Adenovirus ZD55-IL-24 with Histone Deacetylase Inhibitor SAHA
原文传递
导出
摘要 研究组蛋白去乙酰化酶抑制剂SAHA联合溶瘤腺病毒ZD55-IL-24对结肠癌SW480细胞的体外杀伤作用。采用MTT法、结晶紫实验检测SAHA、ZD55-IL-24以及二者联合使用对结肠癌细胞株SW480及人正常肺上皮细胞株Beas-2B的增殖抑制作用;利用Hoechst33342染色对经各种处理的细胞进行凋亡形态学观察,采用流式细胞术对凋亡进行量化;通过Western blot法在蛋白水平上检测SW480细胞中IL-24的表达情况。结果显示SAHA与ZD55-IL-24联合处理对SW480的增殖抑制作用明显优于两者单独使用。10 MOI病毒ZD55-IL-24与0.5μmol/L SAHA联合作用4天,SW480细胞存活率仅为12%,明显低于10 MOI病毒单独处理组细胞的存活率(40%,P<0.05)。然而,正常细胞对于联合给药显示出良好的耐受性。Hoechst33342染色和流式细胞术结果也表明联合处理组的SW480细胞凋亡特征更明显。此外,IL-24在ZD55-IL-24病毒单独感染组及病毒与药物联合组的SW480细胞中均能有效表达。 To investigate the anti-tumor effects in colorectal cancer cell line SW480 in vitro by combining oncolytic adenovirus ZD55-IL-24 with suberoylanilide hydroxamic acid(SAHA),MTT assay and crystal violet assay were used to determine the growth inhibition effect of single or combination therapy on colorectal cancer cell line SW480 and normal human lung epithelial cell line Beas-2B.After Hoechst33342 staining,the morphological changes of apoptosis in treated cells were observed under fluorescence microscope.And flow cytometry assay was used to quantify apoptosis.The expression level of IL-24 protein was assayed by Western blot.The results of MTT and crystal violet staining showed that the growth inhibition of SW480 cells treated with the combination of ZD55IL-24 and SAHA were more obvious than that in ZD55-IL-24 group or SAHA group alone.Four days after administration of 10 MOI ZD55-IL-24 and 0.5 μmol/L SAHA,the cell viability rate of SW480 cells was only 12%,which was significantly lower than that of cells treated only by 10 MOI ZD55-IL-24(40%,P<0.05).In contrast,Beas-2B cells were spared from inhibition of combined treatment(P<0.05).Hoechst33342 staining and flow cytometry also confirmed that there were much more apoptotic SW480 cells in combinational treatment group.In addition,IL-24 protein was effectively expressed in SW480 cells infected with ZD55-IL-24 alone or treated with ZD55-IL-24 plus SAHA.
出处 《中国细胞生物学学报》 CAS CSCD 北大核心 2012年第1期54-60,共7页 Chinese Journal of Cell Biology
基金 浙江理工大学科研启动基金(No.1016834-Y)资助项目~~
关键词 SAHA 溶瘤腺病毒 IL-24 结肠癌 流式细胞术 细胞凋亡 SAHA oncolytic adenovirus IL-24 colorectal cancer flow cytometry apoptosis
  • 相关文献

参考文献4

二级参考文献101

  • 1Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer[ J]. Eur J Cancer,2005,41 (16) :2381-2402.
  • 2Savickiene J, Treigyte G, Borutinskaite V, et al. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia ceils to retinoic acid-induced differentiation [J]. Ann N Y Acad Sci ,2006,1091:368-384.
  • 3Gao S, Mobley A, Miller C,et al. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells [ J ]. Leuk Res ,2008 ,32 (5) :771-780.
  • 4Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action [ J ]. Oncogene, 2007,26 ( 37 ) : 5541-5552.
  • 5Carey N, La Thangue NB. Histone deacetylase inhibitors: gathering pace[J]. Curt Opin Pharmacol,2006,6(4) :369-375.
  • 6Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors : overview and perspectives[ J]. Mol Cancer Res,2007,5 (10) : 981-989.
  • 7Glozak MA, Sengupta N, Zhang X, et al. Acetylation and deacetylation of non-histone proteins [ J ]. Gene ,2005,363 : 15-23.
  • 8Drummond DC, Noble CO, Kippotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents[ J]. Annu Rev Pharmacol Toxicol, 2005,45 ( 2 ) :495-528.
  • 9Petrie K, Prodrumou N, Zelent A. Histone deaceetylase inhibitors in APL and beyond [J]. Curr Top Microbiol Immunol, 2007,313 : 157-203.
  • 10Rosato RR, Maqqio SC, Almenara JA, et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomy-elinase-dependent generation of ceramide [ J ]. Mol Pharmacol,2006,69 ( 1 ) :216-225.

共引文献58

同被引文献54

  • 1李世荣.大肠癌早期诊断技术的进展[J].继续医学教育,2006,20(3):88-92. 被引量:6
  • 2姚站馨,吕茂民,章金刚.Apoptin与肿瘤细胞凋亡[J].生物技术通讯,2007,18(3):490-492. 被引量:1
  • 3Dent P,Yacoub A,Hamed I-IA,et al. MDA 7/IL 24 as a cancer therapeutic :from bench to bedside[J]. Anticancer Drugs ,2010,21 (8) :725-731.
  • 4Falchook GS,Naing A,Hong DS,et al. Dual EGFR inhibition in combination with anti-VEGF treatment :A phase I clinical trial in non-small cell lung cancer[J]. Oncotarget, 2013,14 ( 1 ) : 118-127.
  • 5Lynch TJ,Bondarenko I,Luft A,et at. Ipilimumab in combination with paclitaxel and carboplatin as rst-line treatment in stage III b/ IV non-small- cell lung cancer:results from a randomized,dou- ble-blind,multicenter phase II study[J]. Clin Oncol,2012,30(17) : 2046-2054.
  • 6Wn YL,Park K, Soo RA,et al. INSPIRE : A phase III study of the BLP25 liposome vaccine(L-BLP25) in Asian patients with unre- sectable stage In non-small cell lung cancer[J]. BMC Cancer, 2011,11:430.
  • 7Quoix E ,Ramlan R,Westeel V,et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer :a controlled phase 2B trial[J]. Lancet Oncol, 2011,12(12):1125-1133.
  • 8Yacoub A,Liu R,Park MA,et al. Cisplatin enhances proteinki- nase R-like endoplasmic reticulum kinase-and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-in- duced killing in ovarian carcinoma cells[J]. Mol Pharmaco1,2010, 77(2) :298-310.
  • 9Azab B,Dash R,Das SK,et al. Enhanced delivery of mda-7/IL- 24 using a serotype chimeric adenovirus (Ad.5/3) improves ther- apeutic efficacy in low CARprostate cancer cells[J]. Cancer Gene Ther,2010,17(7) :447-456.
  • 10Jia J,Li S,Gong W,et at. IL-24 induces apoptasis in human GBC SDgaUbladder carcinoma cells via mitochon drial apoptotic path- way[J]. Oncol Rep,2011,25 ( 1 ) : 195-201.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部